SHAREHOLDERS' EQUITY (Tables)
|
9 Months Ended |
Sep. 30, 2026 |
| Equity [Abstract] |
|
| Schedule of fair value for options granted |
| |
|
Nine Months Ended
September 30,
|
|
| |
|
2026 |
|
|
2025 |
|
| Expected volatility |
|
|
95.1 |
% |
|
|
102.5 |
% |
| Risk-free rate |
|
|
4.1 |
% |
|
|
4.1 |
% |
| Dividend yield |
|
|
- |
|
|
|
- |
|
| Expected term (in years) |
|
|
6.08 |
|
|
|
6.25 |
|
| Share price |
|
$ |
6.53 |
|
|
$ |
1.04 |
|
|
| Schedule of stock options activity |
| |
|
Number |
|
|
Weighted
average
exercise
price
|
|
|
Weighted
average
remaining
contractual
life (years)
|
|
|
Aggregate
intrinsic
value (in
thousands)
|
|
| Options outstanding as of December 31, 2025 |
|
|
52,450 |
|
|
$ |
13.86 |
|
|
|
9.43 |
|
|
$ |
- |
|
| Granted |
|
|
212,692 |
|
|
|
6.53 |
|
|
|
- |
|
|
|
- |
|
| Exercised |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Forfeited |
|
|
(198,025 |
) |
|
|
10.67 |
|
|
|
- |
|
|
|
- |
|
| Options outstanding as of September 30, 2026 |
|
|
67,117 |
|
|
$ |
9.75 |
|
|
|
8.16 |
|
|
$ |
2.8 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options exercisable as of September 30, 2026 |
|
|
13,060 |
|
|
$ |
20.87 |
|
|
|
3.30 |
|
|
$ |
- |
|
|
| Schedule of employee and non-employee RSUs activity |
| |
|
Number of
shares
underlying
outstanding
RSUs
|
|
|
Weighted-
average
grant date
fair value
|
|
| Unvested RSUs as of December 31, 2025 |
|
|
73,433 |
|
|
$ |
15.30 |
|
| Granted |
|
|
118,506 |
|
|
|
7.04 |
|
| Vested |
|
|
(29,593 |
) |
|
|
16.41 |
|
| Forfeited |
|
|
(30,033 |
) |
|
|
11.34 |
|
| Unvested RSUs as of September 30, 2026 |
|
|
132,313 |
|
|
$ |
8.55 |
|
|
| Schedule of options and RSUs outstanding |
| Range of exercise price |
|
|
Options and RSUs
outstanding as of
September 30, 2026
|
|
|
Weighted
average
remaining
contractual
life (years) (1)
|
|
|
Options outstanding and
exercisable as of
September 30, 2026
|
|
|
Weighted
average
remaining
contractual
life (years) (1)
|
|
| |
RSUs |
|
|
|
132,313 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| |
Options: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| $ |
6.53 |
|
|
|
39,994 |
|
|
|
9.49 |
|
|
|
- |
|
|
|
- |
|
| $ |
8.6 |
|
|
|
18,750 |
|
|
|
8.87 |
|
|
|
4,687 |
|
|
|
8.87 |
|
| $ |
14.70 |
|
|
|
8,333 |
|
|
|
0.17 |
|
|
|
8,333 |
|
|
|
0.17 |
|
| $ |
2,257.5-$4,200 |
|
|
|
40 |
|
|
|
1.33 |
|
|
|
40 |
|
|
|
1.33 |
|
| |
|
|
|
|
|
199,430 |
|
|
|
8.16 |
|
|
|
13,060 |
|
|
|
3.30 |
|
| |
(1) |
Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. |
|
| Schedule of non-cash share-based compensation expense |
| |
|
Nine Months Ended
September 30,
|
|
| |
|
2026 |
|
|
2025 |
|
| Cost of revenues |
|
$ |
10 |
|
|
$ |
9 |
|
| Research and development, net |
|
|
104 |
|
|
|
105 |
|
| Sales and marketing |
|
|
99 |
|
|
|
203 |
|
| General and administrative |
|
|
329 |
|
|
|
259 |
|
| Total |
|
$ |
542 |
|
|
$ |
576 |
|
|
| Schedule of warrants outstanding and exercisable |
| Issuance date |
|
Warrants
outstanding
|
|
|
Exercise price
per warrant
|
|
|
Warrants
outstanding
and
exercisable
|
|
|
Contractual
term
|
| |
|
(number) |
|
|
|
|
|
(number) |
|
|
|
| September 29, 2021 (1) |
|
|
95,314 |
|
|
$ |
168.00 |
|
|
|
95,314 |
|
|
March 29, 2027 |
| January 8, 2025 (2) |
|
|
151,514 |
|
|
$ |
33.00 |
|
|
|
151,514 |
|
|
January 10, 2028 |
| January 8, 2025 (3) |
|
|
9,088 |
|
|
$ |
41.25 |
|
|
|
9,088 |
|
|
January 10, 2028 |
| June 26, 2025 (4) |
|
|
333,328 |
|
|
$ |
7.8 |
|
|
|
333,328 |
|
|
June 26, 2030 |
| June 26, 2025 (5) |
|
|
20,000 |
|
|
$ |
9.75 |
|
|
|
20,000 |
|
|
June 26, 2030 |
| March 25, 2026 (6) |
|
|
3,148,147 |
|
|
$ |
5.40 |
|
|
|
3,148,147 |
|
|
March 25, 2031 |
| March 25, 2026 (7) |
|
|
1,006,113 |
|
|
$ |
0.0001 |
|
|
|
1,006,113 |
|
|
No expiration |
| |
|
|
4,763,504 |
|
|
|
|
|
|
|
4,763,504 |
|
|
|